Search clinical trials for: Antithrombin (Recombinant)

Total 3718 results

Novo Nordisk A/S

Terminated

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Inflammation | Ulcerative Colitis

Poland, Croatia, Denmark, Bulgaria, Hungary, Ukraine, Russian Federation
Digna Biotech S.L.

Unknown

Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Cardiotrophin-1 in Healthy Volunteers

Healthy

Spain
Zhejiang Echon Biopharm Limited

Active, not recruiting

Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects

Healthy

China
BioAegis Therapeutics Inc.

Completed

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

Healthy | Volunteers

United States
BMI Korea

Completed

Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.

Health, Subjective

Korea, Republic of
Kunming Hope of Health Hospital

Terminated

Recombinant Adeno-associated Virus Administration for Patients With Menkes Syndrome

Menkes Syndrome

China
Universiti Sains Malaysia

Completed

Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

Massive Hemorrhage | Massive Blood Loss | Massive Blood Transfusion; Thrombocytopenia

Malaysia
Novo Nordisk A/S

Completed

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Trauma | Acquired Bleeding Disorder

United States, Canada
Novo Nordisk A/S

Completed

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's Disease

France
Novo Nordisk A/S

Completed

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

Spain, Sweden, Singapore, Norway, Italy, Switzerland, Australia, Austria, Belgium, Canada, Denmark, Finland, Germany, Netherlands, United Kingdom
Novo Nordisk A/S

Completed

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Healthy | Congenital Bleeding Disorder

United States
Novo Nordisk A/S

Completed

Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

France, Israel, Germany
Merck Sharp & Dohme LLC

Completed

SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)

Ovarian Cancer | Fallopian Tube Cancer | Metastatic Cancer | Primary Peritoneal Cavity Cancer
Genzyme, a Sanofi Company

Completed

Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients

Human Acid Sphingomyelinase Deficiency

United Kingdom, United States
Genzyme, a Sanofi Company

Completed

A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

Fabry Disease

Japan
Pfizer

Completed

Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

Hemophilia B

United States, Spain, Croatia, Serbia, Russian Federation, Canada, Hungary, Italy, Romania
Stallergenes Greer

Terminated

Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients

Allergy

France
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics

Chronic Renal Failure

China
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Acquired Hemophilia A

United States, Italy, United Kingdom, Germany, Austria, Netherlands, France
Takeda
Baxalta Innovations GmbH, now part of Shire

Completed

rVWF IN PROPHYLAXIS

Von Willebrand Disease

United States, Spain, Italy, Turkey, Germany, Russian Federation, Netherlands, France, Canada
Shandong University

Not yet recruiting

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

CTIT-Chemotherapy Induced Thrombocytopenia
Nanfang Hospital of Southern Medical University
The Third Affiliated Hospital of Southern Medical University; The Second People... and other collaborators

Not yet recruiting

Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients

Pneumonia | Thrombocytopenia
Medexus Pharma, Inc.

Terminated

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Hemophilia B

United States, United Kingdom, India
AM-Pharma
PPD

Completed

A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI (STOP-AKI)

Acute Kidney Injury

Spain, United States, France, United Kingdom, Austria, Ireland, Finland, Netherlands, Belgium, Czechia, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Revimmune

Withdrawn

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Umbilical Cord Blood Transplant
University of Cincinnati
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

The Spot Sign for Predicting and Treating ICH Growth Study (STOP-IT)

Intracerebral Hemorrhage

United States, Canada
Zymenex A/S

Completed

Porphozym in the Treatment of Acute Attacks in AIP

Acute Intermittent Porphyria

United States
Grifols Biologicals, LLC

Completed

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

Hemophilia B

Bulgaria
Novo Nordisk A/S

Completed

Use of NovoSeven® in Active Variceal Bleeding

Cirrhosis | Acquired Bleeding Disorder

Germany, United Kingdom, Spain, Taiwan, France, Italy, Austria, Czech Republic, Poland, Denmark, Finland, Hong Kong
Novo Nordisk A/S

Completed

Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury

Trauma | Acquired Bleeding Disorder

India, Spain, Canada, Finland, Germany, Israel, Italy, Netherlands, Singapore, Switzerland, Taiwan
Pfizer

Completed

Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B

Hemophilia B

Korea, Republic of
Novo Nordisk A/S

Withdrawn

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

Trauma | Acquired Bleeding Disorder

United States
Solvay Pharmaceuticals

Terminated

Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Czech Republic, Denmark, Hungary, Latvia, Poland, Russian Federation, Sweden
Jiangsu Province Centers for Disease Control and...
Shenzhen Kangtai Biological Products Co., LTD

Completed

The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines

Hepatitis b
Zensun Sci. & Tech. Co., Ltd.

Recruiting

Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

Chronic Systolic Heart Failure

China
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Acquired Hemophilia A

United States
WestVac Biopharma Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

COVID-19

China
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of California, Los Angeles; Merck... and other collaborators

Active, not recruiting

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV (COVENANT)

HIV Infection | AIDS-Related Human Papillomavirus Infection | High Grade Cervical Squamous Intraepithelial Neoplasia

Uganda, Kenya, Zimbabwe, South Africa, Malawi
The First Hospital of Jilin University

Completed

Phase II/III of Recombinant Human Albumin Injection

Hepatic Ascites

China
Chengdu CoenBiotech Co., Ltd
Beijing Friendship Hospital; Beijing Chest Hospital, Capital Medical University

Completed

Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis

Tuberculosis

China
agnes chen
University of California, Los Angeles; National Institute of Neurological Disorders... and other collaborators

Terminated

Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I

Mucopolysaccharidosis I | Cognitive Decline

United States
Chiesi Farmaceutici S.p.A.

Completed

Lamazym Aftercare Study (rhLAMAN-09)

Alpha-Mannosidosis

Denmark
Phoenix Tissue Repair, Inc.
Phoenix Tissue Repair, a BridgeBio company

Completed

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

Recessive Dystrophic Epidermolysis Bullosa

United States
Corporacion Parc Tauli

Completed

Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell

Prader-Willi Syndrome

Spain
Phoenix Tissue Repair, Inc.

Completed

A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

Recessive Dystrophic Epidermolysis Bullosa

United States
Zymenex A/S
European Commission

Completed

Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

Alpha-Mannosidosis

Belgium, Denmark, Spain, United Kingdom
Joyce Fox
Ultragenyx Pharmaceutical Inc

No longer available

An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient

Mucopolysaccharidosis Type 7

United States
Novo Nordisk A/S

Completed

Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France
Novo Nordisk A/S

Completed

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

United States

Search clinical trials for: Antithrombin (Recombinant)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations